GlassScriptPhysician profile
Timothy Kyle Summers
NPI 1871121723
$11,129.31
in general payments reported to CMS, 2019-2025
12 companies · $10K in 2025
The $10K reported for 2025 was more than what 87% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $175 · 2024: $843 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $10K · Food and Beverage: $1,068 · Entertainment: $61.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $10,000.00 |
| Food and Beverage | $1,068.05 |
| Entertainment | $61.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $10,000.00 | 2025 | |
| Depuy Synthes Sales INC. | $257.47 | 2024 | Na |
| Cerapedics INC. | $160.00 | 2024 | I-Factor Peptide Enhanced Bone Graft |
| Vericel Corporation | $143.26 | 2023 | Maci |
| Prime Surgical, LLC | $129.71 | 2024 | |
| Heraeus Medical, LLC. | $111.34 | 2024 | |
| Biocomposites INC | $97.25 | 2024 | |
| Heron Therapeutics, INC. | $90.51 | 2025 | Zynrelef |
| Kerecis Limited | $72.83 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Medtronic, INC. | $31.71 | 2023 | Mazor X System |
| Ossur Americas, INC. | $21.32 | 2025 | |
| Bioventus LLC | $13.91 | 2024 | Bonescalpel & Sonicone (O.R.) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.